Dear CAH Community Members,

Adrenas Therapeutics, a BridgeBio affiliate, is pleased to share the news that the first participant in the ADventure clinical trial has been dosed with Adrenas' investigational gene therapy for classic congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency. Based on ground-breaking research by Dr. Pierre Bougnères, this milestone marks an important step not only towards a potential new therapy, but possibly also an entirely new way of thinking about treating CAH. If successful, this approach may allow people living with classic CAH to produce their own cortisol and aldosterone, potentially resulting in the reduction or elimination of daily steroids.

After receiving the one-time infusion, the participant was discharged from the hospital research unit as planned. As with any clinical trial, we will learn more about the safety and potential benefits of this new therapy as the trial proceeds. Other patients are currently in the process of screening and consenting for the trial, and enrollment in the ADventure Trial remains open.

We wish to thank the CAH community, patient advocacy group leaders, the staff at the investigational site, and especially our first study participant. We are honored to recognize and share in this milestone together. We will keep the community updated as the study progresses and look forward to continued collaboration in our shared mission.

Sincerely,

Your Adrenas Therapeutics Team

****

Current criteria for trial participation:

- Adults 18 years of age and older
- Diagnosed with classic CAH (simple-virilizing or salt-wasting)
- Managing CAH with glucocorticoids daily (e.g., hydrocortisone, prednisone, methylprednisolone, or dexamethasone)

For information visit http://cahgenetherapy.com and https://clinicaltrials.gov/ct2/show/NCT04783181